The creation, dissemination, and exploitation of knowledge are the keys to unlocking the potential of Ireland's economy.
The creation, dissemination, and exploitation of knowledge are the keys to unlocking the potential of Ireland's economy. Expertiseireland.com is a comprehensive research portal that provides a fast and effective gateway to the island's knowledge base. The portal offers a mechanism for identifying current research locations and support institutions for commercial and social capitalization. It presents in one searchable database up-to-date information on:
For added convenience, the portal also provides email alerts, which are triggered by changes to targeted expert profiles or funding opportunities, and current news that highlights issues relevant to R&D, education, finance, and capital investments.
Expertiseireland.com is directly populated from knowledge management systems originating at Ireland's academic institutions. The portal is designed primarily to help identify industry expertise and to serve as the contact point between those who create new ideas and those who implement them.
By providing a single access point, www.expertiseireland.com facilitates industry-academic collaborations and business-to-business alliances that utilize the world-class expertise and intellectual capital found on the island.
Expertiseireland.com is owned by the Irish Universities Association (Dublin, Ireland), formerly known as the Conference of Heads of Irish Universities. It is funded by InterTradeIreland. You may learn more about the association by visiting www.iua.ie.
International Women’s Day 2025: A Promising Future for Gender Diversity in Pharma
March 8th 2025In an interview with BioPharm International®, Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Biotech EG 427 Raises €27 Million in Series B Funding to Advance Lead Genetic Medicine Candidate
February 24th 2025Co-led by Andera Partners and Bpifrance, the Series B financing will go toward an ongoing Phase Ib/IIa clinical study for EG 427’s lead candidate and to advance the company’s genetic medicines platform.